查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1561421

2024-2032 年按產品（口服避孕藥、子宮內避孕器、注射避孕藥、陰道環等）、荷爾蒙、年齡層、最終用戶和地區分類的荷爾蒙避孕市場報告

Hormonal Contraceptive Market Report by Product (Oral Contraceptive Pills, Intrauterine Device, Injectable Birth Control, Vaginal Rings, and Others), Hormone, Age Group, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

2023年，全球荷爾蒙避孕藥市場IMARC Group達到187億美元。在全球生殖健康和計劃生育意識、婦女賦權不斷增強（特別是在發展中地區）以及全球對避孕藥具的接受和使用不斷增加的推動下，該市場正在穩步成長。

荷爾蒙避孕藥市場分析：

  • 主要市場促進因素：對荷爾蒙避孕藥的需求是由全球範圍內的計劃生育要求和接受程度所推動的。各國政府和非政府組織僅僅致力於降低意外懷孕率，導致了這個市場的成長。
  • 主要市場趨勢：根據荷爾蒙避孕藥市場預測，近期對該市場產生重大影響的趨勢是長效可逆避孕藥（包括子宮內避孕器和埋植劑）的消費增加，因為其更有效且作用時間更長。
  • 地理趨勢：由於較高的意識水平、收入和醫療設施，北美和西歐在荷爾蒙避孕藥的使用方面主要處於領先地位。相反，由於城市化、醫療保健支出和生活方式因素，預計亞太地區將成長最快。
  • 競爭格局：根據荷爾蒙避孕藥市場研究，荷爾蒙避孕藥市場有幾家大型製藥公司，擁有廣泛的產品組合和分銷網路。小型和大型公司都在增加研發 (R&D) 活動的預算撥款，以開發副作用最小的新藥，同時保持消費者便利。
  • 挑戰與機會：雖然各個地理區域存在的文化阻力和監管障礙限制了市場成長，但仍有多種投資個人化避孕解決方案的機會，並關注女性就業增加的未解決的新興市場。

荷爾蒙避孕藥市場趨勢：

提高全球生殖健康意識與教育

荷爾蒙避孕藥在全球的廣泛使用很大程度上取決於生殖健康意識和教育的提高。各國政府和世界衛生組織等相關國際組織不斷宣傳透過安全有效避孕措施實施計劃生育的理念和優勢。根據世界衛生組織統計，到2021年，全球有19億育齡婦女，其中11億需要計劃生育。其中，8.74億人正在使用現代避孕方法，還有1.64億名女性的避孕需求未被滿足。因此，這極大地影響了荷爾蒙避孕藥市場的收入。具體來說，廣泛的全球運動針對女性和男性，讓他們了解控制懷孕的能力以及減少人口快速成長的有效方法。此外，還推出了許多針對青少年和年輕人的教育計劃，為以後的生活中明智的計劃生育決策奠定基礎。這些教育措施只有輔以醫療保健服務和諮詢，使個人能夠區分各種荷爾蒙避孕方法，才能發揮作用。在這方面，全面的全球教育和健康計畫對於確保這些產品在不同地區得到使用是必不可少的。

技術進步與產品創新

新的、更好的荷爾蒙避孕選擇的開發徹底改變了這個領域，也推動了荷爾蒙避孕的市場價值。最近，一種新型超低劑量製劑（20 μg EE 和 3 mg DRSP）已以 24/4 方案上市（Yaz；Bayer AG）。其功效與較舊的 COC 相似，甚至更好，出血模式是可以接受的。此外，藥物傳輸系統的開發正在產生更可靠的產品，更易於管理並產生更少的副作用。延長週期的避孕藥和子宮內避孕器的改進，例如更少的健康危害和更長的使用期限，都滿足了消費者對便利性和生活方式相容性日益成長的需求。此外，這些進步增強了消費者體驗和依從性，從而擴大了市場，因為女性更有可能使用和恢復使用避孕藥具。此外，避孕產品技術的創新利用消費者獲得的興趣、採用和市場選擇來引入更精細的技術。因此，這正在創造積極的荷爾蒙避孕市場前景。

計劃生育的政策措施和資金

政府支持政策和增加計劃生育項目資金等政策促進了荷爾蒙避孕市場的成長。一些地區的政府，特別是發展中國家的政府，已經通過了政策，確保個人能夠獲得避孕藥具，作為公共衛生和婦女賦權措施的一部分。這些政策降低了避孕藥具的成本，使生殖健康服務變得全面並為每個人提供，並將避孕教育納入公共衛生運動。此外，全球財團和機構提供資金幫助服務不足的地區獲得生殖健康服務。所有這些措施都旨在降低成本並說服個人獲得避孕藥具。確保輕鬆、低價地取得荷爾蒙避孕藥具的政策有助於滿足公共衛生需求和其他社會經濟目標。

荷爾蒙避孕藥市場區隔：

IMARC Group提供了每個細分市場的主要趨勢分析，以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據產品、荷爾蒙、年齡層和最終用戶對市場進行了分類。

按產品分類：

  • 口服避孕藥
  • 子宮內避孕器 (IUD)
  • 注射避孕藥
  • 陰道環
  • 其他

口服避孕藥佔據了荷爾蒙避孕藥市場的大部分佔有率

該報告根據產品提供了詳細的市場細分和分析。這包括口服避孕藥、子宮內避孕器 (IUD)、注射避孕藥、陰道環等。報告稱，口服避孕藥佔了最大的佔有率。

口服避孕藥 (OCP) 因其無與倫比的功效、便利性和可用性組合，繼續引領荷爾蒙避孕藥市場，成為最大的產品領域。荷爾蒙避孕藥市場概況表明，由於其安全性，避孕藥是全球最常見的避孕方法，可確保可預測和可靠的計劃生育。除了可靠性之外，這些產品的市場還因配方的多樣性而多樣化，藥丸有組合版本和純黃體素版本，反映了醫療和消費者的偏好。此外，市場趨勢取決於 OCP 與其他長期荷爾蒙結合避孕藥相比的價格，以及基於 OCP 長期使用歷史的記錄的便利性，儘管有副作用，但仍然安全。同時，該領域仍在發展中，許多新的選擇已經並將繼續開發，以減少副作用並提高荷爾蒙製劑的安全性和舒適性。整體而言，避孕 OCP 仍然是全世界婦女生殖健康的前提。

荷爾蒙分解：

  • 僅含黃體素的避孕藥
  • 複方荷爾蒙避孕藥

複方荷爾蒙避孕藥產業佔有率最大

荷爾蒙避孕藥市場研究報告還提供了基於荷爾蒙的詳細市場細分和分析。這包括純孕激素避孕藥和合併荷爾蒙避孕藥。報告稱，複方荷爾蒙避孕藥佔據了最大的市場佔有率。

荷爾蒙細分市場以複方荷爾蒙避孕藥（CHC）為主。促成該細分市場高佔有率的主要因素是其極高的避孕功效以​​及顯著的健康益處。在有益效果中，值得一提的是保證月經週期的持續時間和月經的嚴重程度、預防卵巢囊腫以及顯著降低子宮內膜癌的風險。 CHC 有丸劑、陰道環和貼片形式，讓使用者可以選擇最方便的給藥方式。因此，CHC 由於其極大的靈活性和額外的健康益處，對廣大用戶來說是一個有吸引力的選擇。在這些擔憂中，一些臨床醫生提到了情緒障礙的風險和體重增加的可能性。然而，持續的改進旨在降低這些副作用的風險，並提高使用者滿意度和依從性。

按年齡層別分類：

  • 15-24歲
  • 25-34歲
  • 35-44歲
  • 44歲以上

15-24歲代表主導細分市場

該報告根據年齡層對市場進行了詳細的細分和分析。這包括 15-24 歲、25-34 歲、35-44 歲以及 44 歲以上。報告顯示，15-24歲年齡層是最大的族群。

根據已確定的人口分佈和社會特徵趨勢，15-24 歲群體是荷爾蒙避孕藥使用者的最大群體。這個年齡範圍通常指青春期後期和成年早期，這是個人最積極探索和利用避孕方法作為其性健康和生殖健康管理常規的一部分的時期。此外，該細分市場的大幅成長是由於青少年和年輕人性活動的增加，以及教授安全性行為和促進避免意外懷孕的廣泛教育計劃的支持。因此，這也對荷爾蒙避孕藥市場統計數據產生正面影響。教育機構、醫療保健提供者和社區組織特別關注這個年齡段，進行各種外展活動和諮詢，讓人們更容易獲得有關不同避孕方法的資訊。同樣，在組建家庭之前建立職業或完成教育的願望也鼓勵這些年輕人尋求充足、安全和可靠的避孕選擇，從而為該子市場的強大代表性做出了重大貢獻。

按最終用戶分類：

  • 醫院和診所
  • 居家護理
  • 門診手術中心
  • 其他

居家照護在市場上表現出明顯的主導地位

報告還提供了基於最終用戶的詳細市場細分和分析。這包括醫院和診所、家庭護理、門診手術中心等。報告顯示，家庭護理佔據了最大的市場佔有率。

荷爾蒙避孕藥市場的主要最終用戶是家庭護理領域，這得益於其提供的便利性和隱私性。鑑於當前消費者要求在舒適的家中做出醫療保健決定的趨勢，對可自我管理的產品的需求必然會增加。避孕藥具比以往任何時候都更容易獲得，這一事實進一步促進了這一趨勢。例如，口服藥丸、經皮貼片和陰道環現在無需任何人的幫助即可使用，並且在世界大部分地區的市場上都很容易買到。根據荷爾蒙避孕藥市場分析，許多線上平台和遠距醫療服務使獲得這些產品變得容易，從而增強了在家中管理避孕需求的吸引力。此外，家庭護理趨勢與以消費者為中心的醫療保健的整體發展相對應，個人在滿足其健康需求時尋求最佳水平的便利性、保密性和自主性。這些因素大大改變了荷爾蒙避孕藥市場的動態。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美市場領先，佔據最大的荷爾蒙避孕藥市場佔有率

該報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告稱，北美是荷爾蒙避孕藥最大的區域市場。

從地理位置上看，北美是全球荷爾蒙避孕藥的領先市場，因為該地區擁有發達的醫療基礎設施、對避孕藥具類型的高度認知以及政府的大力支持。北美還有幾家領先的製藥公司投資開發更方便、有效、安全的避孕藥。同時，美國人的保健文化最為發達，他們更喜歡提前「吞下」口服藥物，而不是子宮內螺旋。此外，許多類型的避孕藥具都包含在保險範圍內，包括保單，這提高了可近性。公共和私人組織提供的許多教育計畫也宣傳使用避孕藥具的好處。這種全面的支持確保北美不僅是一個大市場，而且是全球荷爾蒙避孕領域的領先地區。

（請注意，這只是關鍵參與者的部分列表，報告中提供了完整列表。）

荷爾蒙避孕藥市場的主要參與者致力於資助研究並提高其產品的功效和安全性。它們不斷減少副作用並提高用戶便利性，以獲得市場認可並保持品質領先地位。此外，包括拜耳公司、輝瑞公司和默克在內的公司希望透過在發展中國家的收購和聯盟來擴大其全球影響力，而這些國家目前對荷爾蒙避孕藥的需求較高。此外，製造商經常宣傳荷爾蒙避孕，並向更多女性宣傳相關優勢。這些進展支持發展目標，同時有助於實現更全面的公共衛生政策目標。

荷爾蒙避孕藥市場新聞：

  • 2024 年 4 月 25 日：默克公司發表聲明，將投資超過 3 億歐元（3.208 億美元）在德國達姆施塔特的總部建立一個新的生命科學研究中心。
  • 2022年1月10日：Agile Therapeutics, Inc.宣布與Afaxys Pharma, LLC建立新的合作夥伴關係，以支持Twirla(R)左炔諾孕酮和炔雌醇經皮系統的推廣。

本報告回答的關鍵問題：

  • 迄今為止，全球荷爾蒙避孕藥市場表現如何，未來幾年將如何表現？
  • 全球荷爾蒙避孕藥市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球荷爾蒙避孕藥市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的荷爾蒙避孕市場？
  • 基於產品的市場區隔是什麼？
  • 荷爾蒙避孕市場上最具吸引力的產品是什麼？
  • 基於荷爾蒙的市場區隔是什麼？
  • 荷爾蒙避孕藥市場上最具吸引力的荷爾蒙是什麼？
  • 市場按年齡層分類是怎樣的？
  • 荷爾蒙避孕藥市場中哪個年齡最具吸引力？
  • 基於最終用戶的市場區隔是什麼？
  • 荷爾蒙避孕藥市場中哪一個對最終用戶最具吸引力？
  • 市場競爭結構如何？
  • 全球荷爾蒙避孕藥市場的主要參與者/公司有哪些？

本報告回答的關鍵問題：

  • 迄今為止，全球荷爾蒙避孕藥市場表現如何，未來幾年將如何表現？
  • 全球荷爾蒙避孕藥市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球荷爾蒙避孕藥市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的荷爾蒙避孕市場？
  • 基於產品的市場區隔是什麼？
  • 荷爾蒙避孕市場上最具吸引力的產品是什麼？
  • 基於荷爾蒙的市場區隔是什麼？
  • 荷爾蒙避孕藥市場上哪種荷爾蒙最有吸引力？
  • 市場按年齡層分類是怎樣的？
  • 荷爾蒙避孕藥市場中哪個年齡最具吸引力？
  • 基於最終用戶的市場區隔是什麼？
  • 荷爾蒙避孕藥市場上哪一個對最終用戶最具吸引力？
  • 市場競爭結構如何？
  • 全球荷爾蒙避孕藥市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球荷爾蒙避孕藥市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依產品

  • 口服避孕藥
    • 市場趨勢
    • 市場預測
  • 子宮內避孕器 (IUD)
    • 市場趨勢
    • 市場預測
  • 注射避孕藥
    • 市場趨勢
    • 市場預測
  • 陰道環
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依激素

  • 僅含黃體素的避孕藥
    • 市場趨勢
    • 市場預測
  • 複方荷爾蒙避孕藥
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：依年齡段

  • 15-24歲
    • 市場趨勢
    • 市場預測
  • 25-34歲
    • 市場趨勢
    • 市場預測
  • 35-44歲
    • 市場趨勢
    • 市場預測
  • 44歲以上
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按最終用戶

  • 醫院和診所
    • 市場趨勢
    • 市場預測
  • 居家護理
    • 市場趨勢
    • 市場預測
  • 門診手術中心
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Afaxys Inc.
    • Agile Therapeutics Inc.
    • Allergan Inc. (AbbVie Inc.)
    • Bayer AG
    • Cipla Limited
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Piramal Group
    • Teva Pharmaceutical Industries Ltd
Product Code: SR112024A4403

The global hormonal contraceptive market size reached US$ 18.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 26.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032. The market is experiencing steady growth driven by global awareness of reproductive health and family planning, the rising empowerment of women, particularly in developing regions, and the growing acceptance and use of contraceptives across the globe.

Hormonal Contraceptive Market Analysis:

  • Major Market Drivers: The demand for hormonal contraceptives is driven by family planning requirements and acceptance across the globe. The various governments and non-governmental organizations that solely try to reduce the rate of unplanned pregnancies are leading to the growth of this market.
  • Key Market Trends: According to the hormonal contraceptive market forecast, the recent trend that will have a major impact on this market is the increasing consumption of long-acting reversible contraceptives including IUDs and implants on account of being more effective and longer action period.
  • Geographical Trends: North America and Western Europe majorly lead in hormonal contraceptive usage due to high awareness levels, income, and healthcare facilities. On the contrary, Asia Pacific is anticipated to grow fastest due to urbanization, healthcare expenditure, and lifestyle factors.
  • Competitive Landscape: According to the hormonal contraceptive market research, the hormonal contraceptives market has several big pharmaceutical companies with extensive product portfolios and distribution networks. Both small and large companies are increasing their budgetary allocation to research and development (R&D) activities to develop new drugs with minimal side effects while maintaining consumer convenience.
  • Challenges and Opportunities: While the existence of cultural resistance and regulatory hurdles in various geographical areas constrain market growth, there remain multiple opportunities to invest in personalized contraceptive solutions and focus on unaddressed emerging markets with an increase in female employment.

Hormonal Contraceptive Market Trends:

Increasing global awareness and education on reproductive health

The extensive utilization of hormonal contraceptives on a global scale is largely dependent on increased awareness and education about reproductive health. Governments and relevant international organizations, such as the World Health Organization, continuously promote the concept and advantages of family planning through safe and effective contraceptive use. According to the World Health Organization, there were 1.9 billion women of reproductive age worldwide in 2021, 1.1 billion of whom need family planning. Of these, 874 million are using modern contraceptive methods, and there are 164 million women with an unmet need for contraception. Thus, this is significantly influencing the hormonal contraceptive market revenue. Specifically, extensive global campaigns target both women and men, informing them about their ability to control pregnancies and effective ways to reduce rapid population growth. Moreover, numerous educational programs targeting teens and young individuals have been rolled out to lay the groundwork for well-informed family planning decisions later in life. These educational initiatives are only effective when complemented by access to healthcare services and consultations that enable individuals to differentiate among various hormonal contraceptive methods. In this regard, comprehensive global educational and health programs are indispensable in ensuring these products are taken up in different regions.

Technological advancements and product innovation

The development of new and better hormonal contraceptive options that revolutionize the area also propels hormonal contraceptive market value. Recently, a novel ultra-low-dose preparation of 20 μg EE and 3 mg DRSP has been marketed in a 24/4 regimen (Yaz; Bayer AG). The efficacy is similar to, if not better than, older COCs, and the bleeding pattern is acceptable. Additionally, drug delivery system development is resulting in more reliable items that are simpler to manage and produce fewer side effects. Extended-cycle pills and improvements to intrauterine devices, such as fewer health hazards and a longer period of utilization, respectively, all address the increasing need for consumer convenience and lifestyle compatibility. In addition, such advancements enhance the consumer experience and compliance, resulting in an expanded market since women are more likely to use and resume contraceptive use. In addition, innovations in contraceptive product technologies take advantage of consumers' acquired interest and adoption and market choice to introduce more refined technologies. Therefore, this is creating a positive hormonal contraceptive market outlook.

Policy initiatives and funding for family planning

Policies, such as supportive government policies and increased funding for family planning programs, facilitate the hormonal contraceptive market growth. Several governments in various regions, particularly in developing countries, have passed policies to ensure that individuals have access to contraceptives as part of public health and women's empowerment measures. These policies lower the cost of contraceptives, make reproductive health services comprehensive and available to everyone, and incorporate contraceptive education in public health campaigns. Furthermore, global consortia and institutions offer funding to help underserved areas access reproductive health services. All these measures seek to reduce the cost and convince individuals to get contraceptives. Policies that guarantee easy and low-priced access to hormonal contraceptives help to meet public health needs and other socio-economic targets.

Hormonal Contraceptive Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, hormone, age group, and end user.

Breakup by Product:

  • Oral Contraceptive Pills
  • Intrauterine Device (IUD)
  • Injectable Birth Control
  • Vaginal Rings
  • Others

Oral contraceptive pills account for the majority of the hormonal contraceptive market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes oral contraceptive pills, intrauterine device (IUD), injectable birth control, vaginal rings, and others. According to the report, oral contraceptive pills represented the largest segment.

Oral contraceptive pills (OCPs) continue to lead the hormonal contraceptive market as the largest product segment due to their unmatched combination of efficacy, convenience, and availability. The hormonal contraceptive market overview suggests that pills are the most common contraceptive method worldwide due to their safety, which secures predictable and reliable family planning. In addition to their reliability, the market for these products is diversified by the variability of formulations, with pills available in combined and progestin-only versions that reflect medical and consumer preferences. Moreover, the market tendency is determined by the price of OCPs in comparison with other long-term hormone-conjugated contraceptives, and the ease of documentation based on the long history of using OCPs that, despite the side effects, remain safe. In confluence with this, the segment is still developing, and many new options have been and continue to be developed to reduce the side effects and enhance the safety and comfort of hormonal formulations. Overall, contraceptive OCPs remain the premise of reproductive health for women worldwide.

Breakup by Hormone:

  • Progestin-only Contraceptive
  • Combined Hormonal Contraceptive

Combined hormonal contraceptive holds the largest share of the industry

A detailed breakup and analysis of the market based on the hormone have also been provided in the hormonal contraceptive market research report. This includes progestin-only contraceptive and combined hormonal contraceptive. According to the report, combined hormonal contraceptive accounted for the largest market share.

The hormone sub-segment is dominated by combined hormonal contraceptives (CHCs). The main factor contributing to the segment's high share is their very high contraceptive efficacy combined with significant health benefits. Among the beneficial effects, it is worth mentioning the guaranteed duration of the menstrual cycle and the severity of menstruation, the prevention of ovarian cysts, and the significant reduction in the risk of endometrial cancer. CHCs are available in the form of pills, vaginal rings, and patches, giving users an additional choice of the form of administration that is most convenient for them. Thus, CHCs are an attractive option for a wide range of users due to their great flexibility and additional health benefits. Among the concerns, some clinicians mention the risk of mood disorders and the likelihood of weight gain. However, ongoing improvements aim to decrease the risk of these side effects, enhancing user satisfaction and adherence.

Breakup by Age Group:

  • 15-24 Years
  • 25-34 Years
  • 35-44 Years
  • Above 44 Years

15-24 years represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the age group. This includes 15-24 years, 25-34 years, 35-44 years, and above 44 years. According to the report, 15-24 years represented the largest segment.

The group of 15-24 years stands out as the largest segment of hormonal contraceptive users, based on identified trends in demographic distribution and social peculiarities. This age range usually refers to late adolescence and young adulthood, a period when individuals are most active in exploring and utilizing contraceptive options as part of their sexual and reproductive health management routines. In addition, the segment's considerable growth is driven by increased sexual activity among adolescents and young individuals, supported by broad educational programs that teach safe sex and promote the avoidance of unplanned pregnancies. Thus, this is also positively influencing the hormonal contraceptive market statistics. Educational institutions, healthcare providers, and community organizations pay special attention to this age group, conducting various outreach activities and consultations to make information about different methods of contraception more accessible. Similarly, the desire to build a career or complete education before starting a family also encourages these young individuals to seek adequate, secure, and reliable contraceptive options, contributing significantly to the strong representation of this submarket.

Breakup by End User:

  • Hospitals and Clinics
  • Homecare
  • Ambulatory Surgical Centers
  • Others

Homecare exhibits a clear dominance in the market

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals and clinics, homecare, ambulatory surgical centers, and others. According to the report, homecare accounted for the largest market share.

The leading end-user in the hormonal contraceptive market is the homecare segment, driven by the convenience and privacy it offers. Given the current trend of consumers demanding to make their healthcare decisions from the comfort of their homes, the demand for products that can be self-administered was bound to increase. This trend is further facilitated by the fact that contraceptives have become more attainable than ever before. Oral pills, transdermal patches, and vaginal rings, for example, can now be utilized without anyone's help and are readily available on the market in most parts of the world. According to the hormonal contraceptive market analysis, many online platforms and telehealth services make access to these products easy, enhancing the appeal of managing contraceptive needs at home. Furthermore, the homecare trend corresponds to the overall developments in consumer-centered healthcare, whereby individuals are seeking optimal levels of convenience, confidentiality, and autonomy in attending to their health needs. These factors have significantly altered the dynamics within the hormonal contraceptive market.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest hormonal contraceptive market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for hormonal contraceptive.

Geographically, North America is the leading market for hormonal contraceptives globally due to the region's well-developed healthcare infrastructure, high awareness about contraceptive types, and strong government support. There are also several leading pharmaceutical companies in North America investing in the development of more convenient, effective, and safe contraceptives. At the same time, Americans are the most developed in terms of the culture of taking care of their health and they prefer to "swallow" an oral agent in advance rather than an intrauterine spiral. Additionally, many types of contraceptives are covered by insurance, including under policies, which enhance accessibility. Numerous educational programs provided by public and private organizations also inform about the benefits of using contraceptives. This comprehensive support ensures that North America is not only a large market but also a leading region in the global hormonal contraceptive space.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the hormonal contraceptive industry include:

  • Afaxys Inc.
  • Agile Therapeutics Inc.
  • Allergan Inc. (AbbVie Inc.)
  • Bayer AG
  • Cipla Limited
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Piramal Group
  • Teva Pharmaceutical Industries Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The major players in the hormonal contraceptive market are committed to funding research and enhancing the efficacy and safety of their products. They consistently reduce side effects and increase user convenience to gain market acceptance and keep quality leadership. Furthermore, firms including Bayer AG, Pfizer, and Merck & Co. want to extend their global footprint through acquisitions and alliances in developing countries, where the hormonal contraceptive demand is currently higher. Additionally, manufacturers frequently promote hormonal contraception and educate more women about the advantages associated. These developments support development goals while aiding more comprehensive public health policy goals.

Hormonal Contraceptive Market News:

  • April 25, 2024: Merck & Co. Inc. makes a statement of investing over €300m ($320.8m) to establish a new Life Science Research Center at its main office located in Darmstadt, Germany.
  • January 10, 2022: Agile Therapeutics, Inc. announced that it has entered into a new partnership with Afaxys Pharma, LLC to support the promotion of the Twirla(R) levonorgestrel and ethinyl estradiol transdermal system.

Key Questions Answered in This Report:

  • How has the global hormonal contraceptive market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global hormonal contraceptive market?
  • What is the impact of each driver, restraint, and opportunity on the global hormonal contraceptive market?
  • What are the key regional markets?
  • Which countries represent the most attractive hormonal contraceptive market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the hormonal contraceptive market?
  • What is the breakup of the market based on the hormone?
  • Which is the most attractive hormone in the hormonal contraceptive market?
  • What is the breakup of the market based on the age group?
  • Which is the most attractive age group in the hormonal contraceptive market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the hormonal contraceptive market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global hormonal contraceptive market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hormonal Contraceptive Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Oral Contraceptive Pills
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Intrauterine Device (IUD)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Injectable Birth Control
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Vaginal Rings
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Hormone

  • 7.1 Progestin-only Contraceptive
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Combined Hormonal Contraceptive
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Age Group

  • 8.1 15-24 Years
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 25-34 Years
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 35-44 Years
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Above 44 Years
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Homecare
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Ambulatory Surgical Centers
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Afaxys Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Agile Therapeutics Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Allergan Inc. (AbbVie Inc.)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Bayer AG
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Cipla Limited
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck & Co. Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Pfizer Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Piramal Group
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
    • 15.3.10 Teva Pharmaceutical Industries Ltd
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hormonal Contraceptive Market: Major Drivers and Challenges
  • Figure 2: Global: Hormonal Contraceptive Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hormonal Contraceptive Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Hormonal Contraceptive Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Hormonal Contraceptive Market: Breakup by Hormone (in %), 2023
  • Figure 6: Global: Hormonal Contraceptive Market: Breakup by Age Group (in %), 2023
  • Figure 7: Global: Hormonal Contraceptive Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Hormonal Contraceptive Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Hormonal Contraceptive (Oral Contraceptive Pills) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Hormonal Contraceptive (Oral Contraceptive Pills) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Hormonal Contraceptive (Intrauterine Device-IUD) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Hormonal Contraceptive (Intrauterine Device-IUD) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Hormonal Contraceptive (Injectable Birth Control) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Hormonal Contraceptive (Injectable Birth Control) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Hormonal Contraceptive (Vaginal Rings) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Hormonal Contraceptive (Vaginal Rings) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Hormonal Contraceptive (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Hormonal Contraceptive (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Hormonal Contraceptive (Progestin-only Contraceptive) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Hormonal Contraceptive (Progestin-only Contraceptive) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Hormonal Contraceptive (Combined Hormonal Contraceptive) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Hormonal Contraceptive (Combined Hormonal Contraceptive) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Hormonal Contraceptive (15-24 Years) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Hormonal Contraceptive (15-24 Years) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Hormonal Contraceptive (25-34 Years) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Hormonal Contraceptive (25-34 Years) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Hormonal Contraceptive (35-44 Years) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Hormonal Contraceptive (35-44 Years) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Hormonal Contraceptive (Above 44 Years) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Hormonal Contraceptive (Above 44 Years) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Hormonal Contraceptive (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Hormonal Contraceptive (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Hormonal Contraceptive (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Hormonal Contraceptive (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Hormonal Contraceptive (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Hormonal Contraceptive (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Hormonal Contraceptive (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Hormonal Contraceptive (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: North America: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: North America: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: United States: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: United States: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Canada: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Canada: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Asia-Pacific: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Asia-Pacific: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: China: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: China: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Japan: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Japan: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: India: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: India: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: South Korea: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: South Korea: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Australia: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Australia: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Indonesia: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Indonesia: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Others: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Europe: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Europe: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Germany: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Germany: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: France: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: France: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: United Kingdom: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: United Kingdom: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Italy: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Italy: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Spain: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Spain: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Russia: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Russia: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Latin America: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Latin America: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Brazil: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Brazil: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Mexico: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Mexico: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Middle East and Africa: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Middle East and Africa: Hormonal Contraceptive Market: Breakup by Country (in %), 2023
  • Figure 87: Middle East and Africa: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Global: Hormonal Contraceptive Industry: SWOT Analysis
  • Figure 89: Global: Hormonal Contraceptive Industry: Value Chain Analysis
  • Figure 90: Global: Hormonal Contraceptive Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hormonal Contraceptive Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hormonal Contraceptive Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Hormonal Contraceptive Market Forecast: Breakup by Hormone (in Million US$), 2024-2032
  • Table 4: Global: Hormonal Contraceptive Market Forecast: Breakup by Age Group (in Million US$), 2024-2032
  • Table 5: Global: Hormonal Contraceptive Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Hormonal Contraceptive Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Hormonal Contraceptive Market: Competitive Structure
  • Table 8: Global: Hormonal Contraceptive Market: Key Players